Chacruna Institute for Psychedelic Plant Medicines is a registered California 501(c)(3) non-profit organization (EIN 84-3076078). We are a community-oriented organization run by a small staff of experts and enthusiastic volunteers who work to bring education and cultural understanding about psychedelic plant medicines to a wider audience. We promote a bridge between the ceremonial use of sacred plants and psychedelic science and envisage a world where plant medicines and other psychedelics are preserved, protected, and valued as part of our cultural identity and integrated into our social, legal, and health care systems.
Help us to achieve our mission! From our beginnings in 2017, we have stood apart from other psychedelic education and advocacy organizations by pioneering initiatives that support and provide a platform for diverse voices, including women, queer people, people of color, Indigenous people, and the Global South. In efforts to address the lack of diverse representation in the expanding psychedelic landscape, we centered our mission around the empowerment of marginalized voices to foster cultural and political reflections on topics like race, gender, and sexuality in psychedelic science. We believe now more than ever, given the current social and political climate, our work is critical to the future of psychedelic healing for humanity.
Please become a member so that you are able to help Chacruna, yourself, and the world. Support of any amount helps this cause and allows us to provide psychedelic education to anyone who wants to access it.
Roger Heim (1900-1979) was a French biologist whose research into psychedelic mushrooms transcended interdisciplinary and transnational lines. Heim collaborated with major figures in the mid-twentieth century psychedelic community, including the Wassons and Hofmann, and appraised their use in divination.
We usually think about the medical systems of indigenous people in terms of plants, rituals, or shamanic chanting. But one very important health strategy...
At a Chacruna retreat in Brazil, Marcelo Leite and other team members took part in a feitio ayahuasca ritual at a Santo Daime church. Leite describes the steps of the ceremony and his experience.
Peyote (Lophophora williamsii) is a small, spineless, mind-altering cactus that, for centuries, has been terribly misunderstood by Western society. It grows naturally in the...
Diana Negrín, Ph.D, reflects on growing up in Guadalajara and listening in to her father, Juan Negrín, pioneer researcher of the Wixarika culture, in conversation about the intersection between Western and Indigenous scientific knowledge with friends from the California psychedelic community like Sasha Shulgin.
Introduction: The Problem We Are Facing in Today’s World
How can we reconnect humanity—mentally, emotionally, and spiritually—to the presently undergoing global ecocide (the destruction, or...
This article explores the idea of the psychedelic experience as a “double-edged sword” in the way that although spiritual revelations and insights can aid in bettering mental health, these revelations and insights can also lead to further damaging the psychology of an individual. The authors explore potential causes and solutions to this dilemma.
Jasmine Virdi interviews Nidia Olvera Hernández, a Mexican ethnohistorian, specializing in the history of psychoactive substances and drug poilices. In this article, Nida shares about some of her earlier research into the history of marijuana in Mexico, detailing cannabis’ arrival with Span-ish colonizers who intended to use the plant for industrial purposes, and how the conception of the plant shifted over time, eventually coming to be referred to as “marijuana” as opposed to “hemp.”
This paper provides a history of the process in which mescaline was synthesized, and 100 years of research involving it. Among these researchers were Ernst Späth, Arthur Heffter, Humphrey Osmond, Aldous Huxley, and Alexander ‘Sasha’ Shulgin. Today, there has been movement for researchers to conduct clinical studies with mescaline through the FDA.